Vaccine Developers Leverage mRNA and Other Powerful Technologies genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
In this final of 3 segments of an interview with ICT, Thomas Rademacher, Emergex co-founder, delves into T cell-based vaccines for chikungunya, likening immune programming to software, emphasizing the urgency of prevention in endemic regions.
The FDA-approved vaccine for chikungunya is out, but is it a safer and more effective solution for preventing this infectious disease? What other options are coming? ICT finds out.